United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. Our lead product, Remodulin, is approved in the U.S. and various countries around the world for both continuous subcutaneous and continuous intravenous infusion for the treatment of pulmonary arterial hypertension (PAH). In addition to prostacyclin analogs like Remodulin, United Therapeutics develops Glycobiological Antiviral Agents for the treatment of infectious diseases, such as Hepatitis C. For more information about United Therapeutics' pipeline, click here

To receive press releases, quarterly and annual SEC filings, please click here.

Current Press Releases

Nov 17, 2008
Lilly Licenses U.S. Rights for Tadalafil PAH Indication to United Therapeutics

Nov 17, 2008
Freedom-C Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Fails to Meet Primary Endpoint

more »

Events

Jan 12, 2009
27th Annual J.P. Morgan Healthcare Conference

more »